scholarly journals A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0200290 ◽  
Author(s):  
Xian Wang ◽  
Shan Huang ◽  
Xiaocan Li ◽  
Dongrui Jiang ◽  
Hongzhen Yu ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Tumors ◽  
Papillary Thyroid ◽  
Potential Biomarker ◽  
Papillary Hyperplasia ◽  
Benign Thyroid

Identification of Differentially Expressed Genes Associated with Papillary Thyroid Carcinoma

2020 ◽  
Vol 23 (6) ◽  
pp. 546-553
Author(s):  
Hongyuan Cui ◽  
Mingwei Zhu ◽  
Junhua Zhang ◽  
Wenqin Li ◽  
Lihui Zou ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Differentially Expressed Genes ◽  
Molecular Mechanisms ◽  
Cellular Proliferation ◽  
Mrna Level ◽  
Thyroid Tissue ◽  
Differentially Expressed ◽  
Thyroid Tumors ◽  
Papillary Thyroid

Objective: Next-generation sequencing (NGS) was performed to identify genes that were differentially expressed between normal thyroid tissue and papillary thyroid carcinoma (PTC). Materials & Methods: Six candidate genes were selected and further confirmed with quantitative real-time polymerase chain reaction (qRT-PCR), and immunohistochemistry in samples from 24 fresh thyroid tumors and adjacent normal tissues. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to investigate signal transduction pathways of the differentially expressed genes. Results: In total, 1690 genes were differentially expressed between samples from patients with PTC and the adjacent normal tissue. Among these, SFRP4, ZNF90, and DCN were the top three upregulated genes, whereas KIRREL3, TRIM36, and GABBR2 were downregulated with the smallest p values. Several pathways were associated with the differentially expressed genes and involved in cellular proliferation, cell migration, and endocrine system tumor progression, which may contribute to the pathogenesis of PTC. Upregulation of SFRP4, ZNF90, and DCN at the mRNA level was further validated with RT-PCR, and DCN expression was further confirmed with immunostaining of PTC samples. Conclusion: These results provide new insights into the molecular mechanisms of PTC. Identification of differentially expressed genes should not only improve the tumor signature for thyroid tumors as a diagnostic biomarker but also reveal potential targets for thyroid tumor treatment.

scholarly journals Validation of MicroRNA-188-5p Inhibition Power on Tumor Cell Proliferation in Papillary Thyroid Carcinoma

2020 ◽  
Vol 29 ◽  
pp. 096368972091830 ◽  
Author(s):  
Ping Zhou ◽  
Andrew Irving ◽  
Huifang Wu ◽  
Juan Luo ◽  
Johana Aguirre ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Tumor Cell ◽  
Cellular Proliferation ◽  
Tumor Cell Proliferation ◽  
Papillary Thyroid ◽  
Tumor Tissues ◽  
Potential Biomarker ◽  
And Function

Given the crucial role of microRNAs in the cellular proliferation of various types of cancers, we aimed to analyze the expression and function of a cellular proliferation-associated miR-188-5p in papillary thyroid carcinoma (PTC). Here we demonstrate that miR-188-5p is downregulated in PTC tumor tissues compared with the associated noncancerous tissues. We also validate that the miR-188-5p overexpression suppressed the PTC cancer cell proliferation. In addition, fibroblast growth factor 5 (FGF5) is observed to be downregulated in the PTC tumor tissues compared with the associated noncancerous tissues. Subsequently, FGF5 is identified as the direct functional target of miR-188-5p. Moreover, the silencing of FGF5 was found to inhibit PTC cell proliferation, which is the same pattern as miR-188-5p overexpression. These results suggest that miR-188-5p-associated silencing of FGF5 inhibits tumor cell proliferation in PTC. It also highlights the importance of further evaluating miR-188-5p as a potential biomarker and therapy target in PTC.

High Prevalence of Occult Papillary Thyroid Carcinoma in a Surgical Series for Benign Thyroid Disease

1990 ◽  
Vol 76 (3) ◽  
pp. 255-257 ◽  
Author(s):  
Maria Rosa Pelizzo ◽  
Andrea Piotto ◽  
Domenico Rubello ◽  
Dario Casara ◽  
Ambrogio Fassina ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Disease ◽  
Benign Thyroid Disease ◽  
Papillary Thyroid ◽  
High Prevalence ◽  
Benign Thyroid

Distinct Metabolomic Profiles of Papillary Thyroid Carcinoma and Benign Thyroid Adenoma

2015 ◽  
Vol 14 (8) ◽  
pp. 3315-3321 ◽  
Author(s):  
Yanan Xu ◽  
Xiaojiao Zheng ◽  
Yunping Qiu ◽  
Wei Jia ◽  
Jiadong Wang ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Adenoma ◽  
Papillary Thyroid ◽  
Benign Thyroid

BRAFK601E Mutation in a Follicular Thyroid Adenoma: A Case Report

2017 ◽  
Vol 25 (4) ◽  
pp. 348-351 ◽  
Author(s):  
Elisabetta Macerola ◽  
Liborio Torregrossa ◽  
Clara Ugolini ◽  
Sohail Bakkar ◽  
Paolo Vitti ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Treatment Plan ◽  
Follicular Adenoma ◽  
Surrounding Tissue ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Thyroid Lesion ◽  
Cytological Smear ◽  
Benign Thyroid

BRAF mutations represent the most common genetic alteration in papillary thyroid carcinoma (PTC). The p.V600E mutation is specific for the classic and tall-cell variants of PTC and has been associated with a more aggressive biologic behavior. On the other hand, the p.K601E mutation is peculiar to the follicular variant of PTC, and seems to be a favorable prognostic indicator. A 12-year-old boy presented with a 10-mm left-sided thyroid nodule. Fine-needle aspiration cytology reported the lesion as suspicious for a follicular neoplasm (Bethesda category IV). The patient underwent lobectomy, and histopathology revealed a follicular adenoma with normal surrounding tissue. The cytological smear was found to be positive for BRAF p.K601E mutation, and this was later confirmed on the corresponding paraffin block. This case was independently revised by 4 expert pathologists, all of whom confirmed the benign nature of the thyroid lesion. This article describes the presence of a BRAF mutation in a benign thyroid lesion. To the authors’ knowledge, this is the fourth case of follicular adenoma carrying BRAFK601E reported in literature to date. BRAFK601E mutation can occur in benign thyroid lesions. This finding, in the context of the current literature and the recently proposed reclassification of the noninvasive encapsulated follicular variant of papillary thyroid carcinoma into a benign lesion, confirms the importance of preoperative BRAF p.K601E testing in offering patients a tailored treatment plan and avoiding overtreatment.

T2* mapping at 3.0T MRI for differentiation of papillary thyroid carcinoma from benign thyroid nodules

2015 ◽  
Vol 43 (4) ◽  
pp. 956-961 ◽  
Author(s):  
Ruoyang Shi ◽  
Qiuying Yao ◽  
Lianming Wu ◽  
Qinyi Zhou ◽  
Qing Lu ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Nodules ◽  
T2 Mapping ◽  
Papillary Thyroid ◽  
3.0T Mri ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

scholarly journals S100A1 is a Potential Biomarker for Papillary Thyroid Carcinoma Diagnosis and Prognosis

2021 ◽  
Vol 12 (19) ◽  
pp. 5760-5771
Author(s):  
Ge Wang ◽  
Han-ning Li ◽  
Xiao-qing Cui ◽  
Tao Xu ◽  
Meng-lu Dong ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Papillary Thyroid ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker
Sign in / Sign up

Export Citation Format

Share Document